Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease.
CONCLUSIONS: In CKD patients with an AVF, there is moderate certainty that ω-3FA supplementation makes little or no difference to preventing patency loss; and in patients with an AVG, it is very uncertain that ω-3FA supplementation prevents patency loss within 12 months.
PMID: 30480758 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Tam KW, Wu MY, Siddiqui FJ, Chan ES, Zhu Y, Jafar TH Tags: Cochrane Database Syst Rev Source Type: research
More News: Bleeding | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Conferences | Databases & Libraries | Dialysis | Gastroenterology | General Medicine | Heart | Hemodialysis | Kidney Transplant | Kidney Transplantation | Omega 3 | Study | Thrombosis | Transplant Surgery | Transplants | Urology & Nephrology